ESR2 and neoplasm: To validate our findings, we used protein data from the TCGA-COAD cohort and found that compared to patients with combined low ERβ + high ERα expression, patients with combined high ERβ + low ERα expression had a better tumor profile and a more favorable prognosis (Figure 7C).